8-K: Evofem Biosciences Reports Increased Phexxi Sales and Reduced Operating Expenses in 2023

Evofem Biosciences announced a significant increase in Phexxi net product sales and a substantial reduction in operating expenses for 2023, alongside a planned acquisition by Aditxt, Inc.

Summary

• Evofem Biosciences reported $18.2 million in net product sales for Phexxi in 2023, up from $16.8 million in 2022.
• The company significantly reduced total operating expenses by 64% year-over-year, from $101.0 million in 2022 to $36.1 million in 2023.
• Sales and marketing expenses decreased by 73% in 2023, totaling $11.7 million compared to $44.0 million in the previous year.
• Research and development costs were reduced by 88%, from $25.0 million in 2022 to $2.9 million in 2023.
• The loss from operations improved by 79%, decreasing from $84.1 million in 2022 to $17.8 million in 2023.
• For the fourth quarter of 2023, net product sales were $4.8 million, a significant increase from $0.2 million in the same period of 2022.
• The company's loss from operations for the fourth quarter of 2023 was $3.4 million, compared to a loss of $12.1 million in the fourth quarter of 2022.
• Evofem has entered into a definitive agreement to be acquired by Aditxt, Inc., with the transaction expected to close in the second half of 2024.

Sentiment

Score: 7

Explanation: The document shows positive trends in sales growth and cost reduction, along with a strategic acquisition, but the company is still loss-making and has a stockholders deficit. The sentiment is positive but tempered by the financial challenges.

Positives

• Phexxi net product sales increased year-over-year, reaching $18.2 million in 2023.
• The company achieved a significant reduction in operating expenses, demonstrating fiscal discipline.
• Sales and marketing expenses were substantially reduced, improving the company's cost structure.
• The loss from operations improved significantly, indicating progress towards profitability.
• The planned acquisition by Aditxt, Inc. is expected to accelerate growth.
• The company secured a lower rebate on Phexxi prescriptions from Medi-Cal, improving profitability.
• The company has seen a significant increase in sales in the fourth quarter of 2023 compared to the same period in 2022.

Negatives

• The company still reported a loss from operations of $17.8 million for the full year 2023.
• The company had only $0.6 million of restricted cash as of December 31, 2023.
• The company has a total stockholders deficit of $(66.510) million as of December 31, 2023.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The acquisition by Aditxt, Inc. is subject to closing conditions and may not be completed as planned.
• The company's ability to maintain sales growth and reduce losses is dependent on various factors, including market conditions and competition.
• The company has a significant stockholders deficit.

Future Outlook

The company anticipates increased Phexxi usage among women using oral contraceptives with GLP-1 agonists and expects the acquisition by Aditxt to accelerate growth. They also expect to benefit from a recent price increase and improved market access.

Management Comments

• Our ongoing revenue growth and improved loss from operations testifies to the strength and persistence of Evofems current sales team, the growing base of users and prescribers of Phexxi nationwide, and the continued expansion of coverage and reimbursement, said Saundra Pelletier, CEO of Evofem Biosciences.

Industry Context

The announcement comes amid growing interest in non-hormonal contraceptive options and the increasing use of GLP-1 agonists, which may impact the effectiveness of oral contraceptives. The acquisition by Aditxt suggests a move towards consolidating women's health product offerings.

Comparison to Industry Standards

• Evofem's 73% reduction in sales and marketing expenses is significant compared to other pharmaceutical companies, which typically see more modest reductions.
• The 88% reduction in research and development costs is also substantial, indicating a shift in focus from development to commercialization.
• The improvement in loss from operations by 79% is a positive sign, but the company still needs to achieve profitability, which is a common challenge for smaller biotech companies.
• Compared to larger pharmaceutical companies like Bayer or Merck, Evofem's revenue is relatively small, but the growth rate is promising.
• The acquisition by Aditxt is similar to other acquisitions in the biotech space where smaller companies are acquired by larger entities to leverage their resources and market reach.

Stakeholder Impact

• Shareholders may view the improved financial results and the acquisition positively.
• Employees may be impacted by the restructuring and acquisition.
• Customers will continue to have access to Phexxi.
• Suppliers may see changes in their relationship with the company due to the acquisition.
• Creditors may be impacted by the company's financial performance and the acquisition.

Next Steps

• The company will focus on increasing Phexxi usage among women using oral contraceptives with GLP-1 agonists.
• The company will continue to execute its Phexxi market access strategy.
• The company will work towards closing the acquisition by Aditxt, Inc. in the second half of 2024.

Key Dates

Keywords

Phexxi, Evofem Biosciences, Net Product Sales, Operating Expenses, Acquisition, Aditxt, Womens Health, Contraceptive, Financial Results, Medi-Cal